Idecabtagene Vicleucel (bb2121)

Overview

bb2121 is a new treatment being investigated in myeloma that belongs to a type of immunotherapy known as chimeric antigen receptor T-cell (CAR-T) therapy. This involves T-cells being taken from the patient and being changed to find myeloma cells more easily. When it finds myeloma cells, bb2121 removes and destroys them.

SparkCures ID 236
Developed By bluebird bio
Generic Name Idecabtagene Vicleucel (bb2121)
Additional Names idecabtagene vicleucel (ide-cel)
Treatment Classifications
Treatment Targets

Clinical Trials

All Clinical Trials

View all active clinical trials around the US.

Untreated / Newly Diagnosed Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have been newly diagnosed or have not yet received treatment.

Early Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.

Late Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.

Smoldering Myeloma
Monoclonal Gammopathy of Undetermined Significance (MGUS)

Published Results

ASCO 2020 Interim Results (bb2121)

May 29, 2020

  • Idecabtagene Vicleucel (bb2121), with the registrational Karmma study, showed some deepening of responses with overall response rate (ORR) rising from 73% to 76% and two more complete responses versus what had been revealed by press release last December.

Resources